The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
Abstract
Purpose: To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling. Patients and Methods: The study was performed on 112 estrogen receptor–positive primary breast carcinomas from patients with advanced disease and clearly defined types of response (ie, 52 patients with objective response v 60 patients with progressive disease) from start of first-line treatment with tamoxifen. Main clinical end points are the effects of therapy on tumor size and time until tumor progression (progression-free survival [PFS]). RNA isolated from tumor samples was amplified and hybridized to 18,000 human cDNA microarrays. Results: Using a training set of 46 breast tumors, 81 genes were found to be differentially expressed (P ≤ .05) between tamoxifen-responsive and -resistant tumors. These genes were involved in estrogen action, apoptosis, extracellular matrix formation, and immune response. From the 81 genes, a predictive signature of 44 genes was extracted and validated on an independent set of 66 tumors. This 44-gene signature is significantly superior (odds ratio, 3.16; 95% CI, 1.10 to 9.11; P = .03) to traditional predictive factors in univariate analysis and also significantly related with a longer PFS in univariate (hazard ratio, 0.54; 95% CI, 0.31 to 0.94; P = .03) as well as in multivariate analyses (P = .03). Conclusion: Our data show that gene expression profiling can be used to discriminate between breast cancer patients with progressive disease and objective response to tamoxifen. Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Yang, Y. H. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.e15 · Cited by 3,464
Exploring the new world of the genome with DNA microarrays
Brown, P. O., & Botstein, D. (1999) · Nature Genetics · doi:10.1038/4462 · Cited by 2,414
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Frasor, J., Danes, J. M., Komm, B., Chang, K. C. N., Lyttle, C. R., & Katzenellenbogen, B. S. (2003) · Endocrinology · doi:10.1210/en.2003-0567 · Cited by 876
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho, J. S., & Pusztai, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61539-0 · Cited by 729
Converting a breast cancer microarray signature into a high-throughput diagnostic test
Glas, A. M., Floore, A., Delahaye, L. J., Witteveen, A. T., Pover, R. C., Bakx, N., Lahti-Domenici, J. S., Bruinsma, T. J., Warmoes, M. O., Bernards, R., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-278 · Cited by 494
Weigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Sotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“In earlier studies we also observed an association between (TGFbeta-induced) ECM remodeling during EMT and chemotherapy resistance in ovarian cancer [18,79] as well as endocrine therapy resistance in breast cancer [80–82].”
BackgroundLoi, S., Haibe-Kains, B., Desmedt, C., Wirapati, P., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Ryder, K., Reid, J. F., et al. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-239 · Cited by 389
Self-citationFoekens, J. A., Atkins, D., Zhang, Y., Sweep, F. C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A. M., Talantov, D., Span, P. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9115 · Cited by 361
Self-citationEstrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers
Oh, D. S., Troester, M. A., Usary, J., Hu, Z., He, X., Fan, C., Wu, J., Carey, L. A., & Perou, C. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2755 · Cited by 356
Resistance to chemotherapy: new treatments and novel insights into an old problem
Raguz, S., & Yagüe, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604510 · Cited by 312
Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer
Mostert, B., Sleijfer, S., Foekens, J. A., & Gratama, J. W. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.03.004 · Cited by 282
Self-citationPathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
Ma, X.-J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., & Erlander, M. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6944 · Cited by 252
Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them)
Berrar, D., & Flach, P. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbr008 · Cited by 136
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
Robertson, C. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.11.009 · Cited by 45
Metadata
- Authors
- Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., Meijer-van Gelder, M. E., Sieuwerts, A. M., Portengen, H., Dorssers, L. C. J., Klijn, J. G. M., & Berns, E. M. J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-01
- Volume
- 23
- Issue
- 4
- Pages
- 732-740
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2143185770
- Cited by
- 340
- References
- 33
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.